Last reviewed · How we verify
Beclomethasone (QVAR)
Beclomethasone (QVAR) is a Inhaled corticosteroid Small molecule drug developed by University Medical Center Groningen. It is currently FDA-approved for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD). Also known as: QVAR.
Beclomethasone is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory mediator production.
Beclomethasone (QVAR) is a small molecule medication used to treat conditions such as asthma, chronic graft-versus-host disease, pulmonary disease, and chronic obstructive pulmonary disease. It is administered via a dry powder inhaler, often in combination with other medications like formoterol.
At a glance
| Generic name | Beclomethasone (QVAR) |
|---|---|
| Also known as | QVAR |
| Sponsor | University Medical Center Groningen |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Beclomethasone acts as a topical anti-inflammatory agent in the lungs, inhibiting the release of inflammatory cytokines, chemokines, and adhesion molecules from immune cells. This reduces mucus production, airway edema, and bronchial hyperresponsiveness. QVAR is a hydrofluoroalkane (HFA) formulation that provides enhanced lung deposition compared to older chlorofluorocarbon formulations.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Oropharyngeal candidiasis
- Dysphonia/hoarseness
- Tremor
- Headache
- Nervousness/anxiety
Key clinical trials
- Study in Adult Patients With Moderate to Severe Asthma (PHASE3)
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting
- Directed Topical Drug Delivery for Treatment for PASC Hyposmia (PHASE2)
- Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients (PHASE3)
- Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)
- Effects of Beclometasone Dipropionate/Formoterol Fumarate Via NEXT(Haler) in a Real-world Study on Asthma Control
- Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Beclomethasone (QVAR) CI brief — competitive landscape report
- Beclomethasone (QVAR) updates RSS · CI watch RSS
- University Medical Center Groningen portfolio CI
Frequently asked questions about Beclomethasone (QVAR)
What is Beclomethasone (QVAR)?
How does Beclomethasone (QVAR) work?
What is Beclomethasone (QVAR) used for?
Who makes Beclomethasone (QVAR)?
Is Beclomethasone (QVAR) also known as anything else?
What drug class is Beclomethasone (QVAR) in?
What development phase is Beclomethasone (QVAR) in?
What are the side effects of Beclomethasone (QVAR)?
What does Beclomethasone (QVAR) target?
Related
- Drug class: All Inhaled corticosteroid drugs
- Target: All drugs targeting Glucocorticoid receptor
- Manufacturer: University Medical Center Groningen — full pipeline
- Therapeutic area: All drugs in Respiratory/Pulmonology
- Indication: Drugs for Asthma maintenance therapy
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD)
- Also known as: QVAR
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing